GeoVax Labs Inc
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
GOVX$0.14-9.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Description |
| 4.1 | Form of Pre-Funded Warrant, dated March 25, 2025 (2) |
| 4.2 | Form of Common Stock Purchase Warrant, dated March 25, 2025 (2) |
| 4.3 | Warrant Amendment Agreement, dated March 23, 2025 (2) |
| 10.1 | Securities Purchase Agreement, dated March 23, 2025 (2) |
| 31.1* | Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 |
| 31.2* | Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 |
| 32.1* | Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2* | Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Inline XBRL Instance Document (1) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document (1) |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document (1) |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document (1) |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document (1) |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document (1) |
| 104 | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q and included in the Exhibit 101 Inline XBRL Document Set (1) |
| * | Filed herewith |
|---|
| ** | Indicates a management contract or compensatory plan or arrangement |
|---|
| (1) | These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections. |
| (2) | Incorporated by reference from the registrant’s Current Report on Form 8-K filed March 25, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.
| GEOVAX LABS, INC. | ||
| (Registrant) | ||
| Date: May 1, 2025 | By: | /s/ Mark W. Reynolds |
|---|---|---|
| Mark W. Reynolds | ||
| Chief Financial Officer | ||
| (duly authorized officer and principal financial officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.